2025年以来,港股医药板块在经历此前多年的深度调整后,走出了一轮亮眼的估值修复行情。伴随一系列创新药支持政策持续出台,以及美联储降息周期带来的流动性改善,市场对生物科技公司的风险偏好逐步修复。而当下随着中国资产牛市行情的持续演绎,市场资金也正积极寻找具备核心技术壁垒、商业化路径清晰且具长期价值潜力的差异化标的。近日,专注于吸入制剂这一高技术壁垒赛道的长风药业成功登陆港交所,不妨就此来看看公司的...
Source Link2025年以来,港股医药板块在经历此前多年的深度调整后,走出了一轮亮眼的估值修复行情。伴随一系列创新药支持政策持续出台,以及美联储降息周期带来的流动性改善,市场对生物科技公司的风险偏好逐步修复。而当下随着中国资产牛市行情的持续演绎,市场资金也正积极寻找具备核心技术壁垒、商业化路径清晰且具长期价值潜力的差异化标的。近日,专注于吸入制剂这一高技术壁垒赛道的长风药业成功登陆港交所,不妨就此来看看公司的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.